Our vision is to transform preclinical therapeutic development with best-in-class human cell-based model systems and reduce reliance on animal models in discovery pipelines. At Altis Biosystems, our mission is to develop advanced cell-based assays that bridge the gap between preclinical research and clinical translation. Our goal is to create clinically translatable assays that accelerate the transition of promising therapies from the bench to the bedside, ultimately improving patient outcomes and reducing animal use in research. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer. We strive to provide researchers with reliable and predictive tools that accurately recapitulate human biology, enabling faster and more efficient drug discovery and development. Altis’ mission is to provide scientific innovation, through collaborative relationships, by helping companies develop safer and more effective therapies to treat patients suffering from human disease. Model systems provide us with valuable insights into disease mechanisms and enable effective evaluation of potential treatments. These innovative systems overcome the constraints of conventional cell lines and animal models, providing a highly accurate representation of human intestinal physiology.
Durham, United States
Founded in 2015
1-10 Employees
Working industry
Biotechnology
Type of company
Manufacturer, Service provider
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
Scientific Research and Development Services, Health Care, Life Science, Biotechnical research, commercial, Biotechnology, Professional, Scientific, and Technical Services
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Altis Biosystems operates in 1 country around the world
Get an overview of the locations of Altis Biosystems
Location
Country
State
City
Headquarter
United States
North Carolina
Durham
Some frequent questions that have been asked about Altis Biosystems
Where is Altis Biosystems located?
The company headquarter of Altis Biosystems is located in Durham, North Carolina, United States. It's worth noting, that the company may have more locations
How many employees does Altis Biosystems approximately have?
As of the latest available information Altis Biosystems has around 1-10 employees worldwide.
When was Altis Biosystems founded?
Altis Biosystems was founded in 2015
In which industries does Altis Biosystems mainly work?
The company Altis Biosystems has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Altis Biosystems
Cherry Biotech
Rennes, France
11-50 Employees
2014
We are convinced that the technological convergence of Microfluidic Organ-On-Chip, Multi-omics, the most advanced imaging techniques and artificial intelligence will allow to better predict drugs effects on the human body and bring the possibility to replace animal testing. Our mission is to develop a technological platform combining microfluidic technology, artificial intelligence, and the most advanced imaging techniques allowing the scientific paradigm shift from animal to 3D In vitro toxicology and efficacy prediction. Our mission is to develop an Organ-On-Chip platform that will provide massive and high-quality biological data coming from Multi-Omic analysis & the most advanced imaging techniques. We are all passionate about improving human health and animal wellfare. To succeed in our mission, we have also built a strong culture based on 3 major axes :. We provide both standard and customized in vitro studies that can be used to screen your new therapeutic candidates, explore the mechanisms of action of drugs or biologics, and accelerate the design of clinical trials. Allowing comprehension and predicting of human responses earlier, while also offering ethical alternatives to animal testing. To reduce and replace animal testing to predict drugs effects on human body, we are convinced that we can reach the full potential of drug prediction by combining Artificial Intelligence, Microfluidic instruments, Multi Omic Sensors and High-resolution live Imaging.
Newcells Biotech
Newcastle upon Tyne, United Kingdom
1-10 Employees
2015
We are experts in building and applying complex models of human tissues for drug discovery. We are cell biologists, tissue physiologists and assay development scientists focused on building models that balance complexity, functionality, throughput and efficiency to improve the predictive power of in vitro data. We carry out in vitro studies or provide products that enable customers to generate data on efficacy, safety and transport to de-risk discovery and development. Our experts collaborate with customers to design studies to provide data that answer critical questions for pre-clinical drug development. We run the study, provide and interpret the data, or we can supply products and support you in your in-house studies. We aim to contribute to the development of new innovative therapies by delivering services, products and tools based on our models of human tissues that provide data that informs and predicts how these therapies will behave in humans. Newcells mission is to de-risk the decision-making process in drug development by providing physiologically relevant in vitro models that most accurately predict in vivo outcomes. Globally recognised scientific expertise in cell physiology and organoid technology is embedded in all products & services.
Humana Biosciences
Labège, France
1-10 Employees
2017
Our mission is to reduce the number of inefficacious candidates moving through to the later stages of clinical investigation by developing innovative experimental models (in vitro and in vivo). That is why our mission is to develop and commercialize in vitro experimental models based on the use of human cells and tissues coming from patients having the pathology of interest. HUMANA BIOSCIENCES IS A PRE-CLINICAL contract research organization (CRO) with a large expertise in Respiratory, Gastro-Intestinal and Uro-Genital therapeutics areas. Every study we conduct is a custom designed study tailored specifically for the client. Our objective is to offer our customers the best predictive experimental models for chronic functional pathologies. Most of the time, the pre-clinical pharmacology for many of these agents is established in cell culture, an oversimplified physiological microenvironment. At Humana Biosciences we believe that drug screening can be improved with the use of human cells ideally derived from patients and then cultured in the most physiologically relevant conditions. Moreover, in our laboratories, we are constantly working to set up the most relevant models of experimental pathologies to be used for in vivo proof of concept, based on the best predictive animal species and phenotypes, including transgenic animals.
Araceli Biosciences
Portland, United States
11-50 Employees
-
Our goal is to develop innovative products that accelerate basic research, drug discovery, and manufacturing to advance healthy outcomes. Araceli Biosciences delivers high-performance scientific tools for tissue and cell-based biomarker discovery, drug discovery and drug development. With decades of combined biomedical research and instrument design experience, we are focused on developing scientific instrumentation to improve outcomes and enable our customers to advance scientific and medical research. Speed is essential for furthering our understanding of biology, and we believe in reducing the time needed to acquire high-quality data and obtain clear, high-quality results. By making advanced technologies accessible, we allow researchers to focus on the science, not the tool. We believe in blurring the line between science and technology, using one to improve the other in a holistic approach.
Hesperos
Orlando, United States
11-50 Employees
2015
Our mission is to accelerate drug development by providing safety and efficacy data of chemicals & novel therapeutics for the pharmaceutical, cosmetic, and food industries. We are funded and collaborate with the best. Founded in 2015, Hesperos, Inc was established by Drs. As a company, this is done by offering development of custom models with up to 5-organ or tissue types. With these models, we're able to provide pre-clinical insight into the efficacy and off-target toxicity of single and multi-drug treatments. Services focus on custom build as well as standard systems composed of human cells representing select organs in a functional, interconnected platform providing pre-clinical insight into how the human body will respond to drug compounds. This is the first time data was used from a microphysiological system which led to the authorization of a clinical trial exclusively using efficacy data from an organ-on-a-chip system marking a significant milestone in validating the technology. Shuler has over 25 years of experience in Body-on-a-Chip research and helped to define the field itself.
InVivo Biosystems
Eugene, United States
51-100 Employees
2011
Providing end-to-end services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions accelerate research and innovation. InVivo Biosystems And Thaena Announce Novel Metabolite Research Platform With Compelling Longevity And Healthspan Implications And Outcomes. Bridge the data gap between cell culture and rodent models. Rapidly conduct preclinical studies to de-risk your clinical trial. An expert in CRISPR genome editing for creating custom genome edited zebrafish and C. elegans, our CRISPR genome editing platform enables preclinical studies and drug discovery by providing insights you need to derisk your clinical trial or decide the next phase of product devleopment.